Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.
Click here to learn how we are responding.

Indication Tooltip

LORBRENA ® (lorlatinib) is a prescription medicine that is used to treat adults with non-small cell lung cancer (NSCLC) that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene and that has spread to other parts of your body.

Your healthcare provider will perform a test to make sure that LORBRENA is right for you.

It is not known if LORBRENA is safe and effective in children.

What is Lorbrena?

Lightbulb icon

LORBRENA is a prescription medicine that is used to treat adults with non-small cell lung cancer (NSCLC) that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene and that has spread to other parts of your body.

LORBRENA is available in a 100-mg strength tablet and a 25-mg strength tablet.

 

How Lorbrena Works

pill bottle icon

LORBRENA was designed to inhibit the ALK protein, including ALK that has become resistant to other ALK inhibitors. Inhibiting the ALK protein can help LORBRENA slow the growth or spread of ALK+ tumors that have spread to other parts of the body.

brain icon

How LORBRENA Works in the Brain

The brain is a common site where ALK+ NSCLC spreads (metastasizes). One reason treating brain metastases can be challenging is that the medicine must cross the blood-brain barrier. The blood-brain barrier is a naturally occurring network of blood and tissue that helps prevent harmful substances, like bacteria, from entering the brain. LORBRENA was specifically designed to cross the blood-brain barrier and has been shown to help shrink ALK+ NSCLC tumors that have spread to the brain.

 

Understanding LORBRENA

LORBRENA Clinical Trial Results in Newly Diagnosed Patients

LORBRENA was evaluated in a clinical trial of 296 patients with ALK+ NSCLC whose cancer had spread to other parts of the body, including the brain. LORBRENA was compared to crizotinib, which is a different treatment for ALK+ NSCLC. All of the patients included in this trial were newly diagnosed and had not taken any treatment for their cancer.

The primary endpoint of this trial was progression-free survival, which is the length of time patients are living without their tumors growing or spreading (“progressing”).

LORBRENA reduced the risk of cancer growing or spreading by 72% compared to crizotinib. After a medianThe median is the middle number in a set of numbers arranged from least to greatest. Half of patients are above and half are below this middle number.The median is the middle number in a set of numbers arranged from least to greatest. Half of patients are above and half are below this middle number. of 9.3 months, half of crizotinib patients were living without their tumors growing or spreading, and half were not. At the time of the analysis, more than half of LORBRENA patients were still living without their tumors progressing. Therefore, the medianThe median is the middle number in a set of numbers arranged from least to greatest. Half of patients are above and half are below this middle number.The median is the middle number in a set of numbers arranged from least to greatest. Half of patients are above and half are below this middle number. time point when half of patients were living without their tumors progressing is not yet known for LORBRENA. More time is needed to determine whether or not LORBRENA helps patients live longer.

This study also assessed the overall response rate. This measures tumor response to treatment, including tumor shrinkage, throughout the body or specifically within the brain. In this study, 76% of patients had their tumors shrink or disappear with LORBRENA.

48 percent orr graph

3% of patients taking LORBRENA had all signs of cancer completely disappear (known as a complete response, although this does not mean the cancer is cured) compared to 0% of patients taking crizotinib

73% of patients taking LORBRENA had their tumors shrink (known as a partial response) compared to 58% of patients taking crizotinib

These responses were ongoing in the majority of patients taking LORBRENA and lasted at least 12 months in 70% of patients. In patients taking crizotinib, responses lasted for a medianThe median is the middle number in a set of numbers arranged from least to greatest. Half of patients are above and half are below this middle number.The median is the middle number in a set of numbers arranged from least to greatest. Half of patients are above and half are below this middle number. of 11 months, and lasted at least 12 months in 27% of patients.

In a smaller group of 17 patients who had measurable brain tumors,* 82% of patients had their brain tumors shrink or disappear with LORBRENA.

82 percent responded

12 out of 17, or 71%, of patients taking LORBRENA had their brain tumors completely disappear (known as a complete response), although this does not mean the cancer is cured), compared to 1 out of 13, or 8%, of patients taking crizotinib

2 out of 17, or 12%, of patients taking LORBRENA had their brain tumors shrink (known as a partial response), compared to 2 out of 13, or 15%, of patients taking crizotinib

These responses lasted at least 12 months in 79% of patients treated with LORBRENA and 0% of patients treated with crizotinib.

*Of the 296 patients in the trial, 78 had brain tumors at the start of treatment, including 30 patients who had brain tumors at the start of treatment, that could be measured. Of those 30 patients, 17 were treated with LORBRENA.

LORBRENA Clinical Trial Results in Previously Treated Patients

LORBRENA was also evaluated in a clinical trial of 215 previously treated patients with ALK+ NSCLC that had spread to other parts of the body, including the brain, and whose tumors were no longer responding to certain other medicines for ALK+ NSCLC.

This study assessed the overall response rate in previously treated patients. In this study, nearly half of patients had their tumors shrink or disappear with LORBRENA.

48 responded

4% of patients treated with LORBRENA had all signs of cancer completely disappear (known as a complete response, although this does not mean the cancer is cured)

44% of patients treated with LORBRENA had their cancer shrink (known as a partial response)

These responses lasted for medianThe median is the middle number in a set of numbers arranged from least to greatest. Half of patients are above and half are below this middle number.The median is the middle number in a set of numbers arranged from least to greatest. Half of patients are above and half are below this middle number. of 12.5 months.

In a smaller group of 89 patients who had measurable brain tumors* that were no longer responding to certain other medicines for ALK+ NSCLC, 60% of patients had their brain tumors shrink or disappear with LORBRENA.

60 responded

19 out of 89, or 21%, of patients taking LORBRENA had their brain tumors completely disappear (known as a complete response, although this does not mean the cancer is cured)

34 out of 89, or 38%, of patients taking LORBRENA had their brain tumors shrink (known as a partial response)

These responses lasted for medianThe median is the middle number in a set of numbers arranged from least to greatest. Half of patients are above and half are below this middle number.The median is the middle number in a set of numbers arranged from least to greatest. Half of patients are above and half are below this middle number. of 19.5 months.

*Of the 215 patients in the trial, 148 (69%) had brain tumors at the start of treatment, including 89 patients who had brain tumors that could be measured.

Hear a real patient discuss her EXPERIENCE WITH LORBRENA

Image of Gina

"I knew that LORBRENA was an option for me" -Gina, LORBRENA patient

Watch Gina's story

Turn to Pfizer Oncology Together™ to learn about financial assistance resources and get personalized support from one of our dedicated Care Champions.